<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167411</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-458</org_study_id>
    <nct_id>NCT03167411</nct_id>
  </id_info>
  <brief_title>Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug-drug interaction when given the study drug,&#xD;
      bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor&#xD;
      agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how&#xD;
      well the study drug is tolerated when administered with exenatide injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 1, single center, open-label, 2 × 2 crossover study designed to assess the&#xD;
      effects of exenatide injection on the PK and PD of orally administered bexagliflozin tablets.&#xD;
      Healthy subjects were randomly assigned to one of two groups with 10 subjects per group. Each&#xD;
      group received both the treatments, alternately, in a crossover fashion with the two&#xD;
      treatment periods separated by a 7-day washout period.&#xD;
&#xD;
      In Treatment Period 1, subjects were admitted to the clinic on day 0, the day before dosing,&#xD;
      and stayed in the clinic until 48 h post-dose. After an overnight fast of at least 10 h,&#xD;
      subjects in Group 1 received a single oral dose of bexagliflozin tablets, 20 mg, alone 30 min&#xD;
      before breakfast, and subjects in Group 2 received a subcutaneous (SC) injection of exenatide&#xD;
      at 10 µg twice a day (bid) with an initial dose 30 min prior to a single oral dose of&#xD;
      bexagliflozin tablets, 20 mg, and 1 hr before breakfast, followed by the second dose of&#xD;
      exenatide alone 1 hr prior to the evening meal.&#xD;
&#xD;
      In Treatment Period 2, subjects were admitted to the clinic on day 7, the day before dosing,&#xD;
      and stayed in the clinic until 48 hr post-dose. After an overnight fast of at least 10 h,&#xD;
      subjects in Group 1 received a SC injection exenatide at 10 µg bid with an initial dose 30&#xD;
      min prior to a single oral dose of bexagliflozin tablets, 20 mg, and 1 hr before breakfast&#xD;
      and followed by the second dose of exenatide alone 1 hr prior to the evening meal. Subjects&#xD;
      in Group 2 received a single oral dose of bexagliflozin tablets, 20 mg, alone 30 minutes&#xD;
      before breakfast.&#xD;
&#xD;
      Blood samples for bexagliflozin plasma concentration were collected during each period at&#xD;
      pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 hr post-dose. Pre-dose&#xD;
      urine samples were collected from -12 to 0 hr for baseline measurement of PD parameters.&#xD;
      Post-dose urine samples were collected in four batches: 0 to 12 hr, 12 to 24 hr, 24 to 36 hr,&#xD;
      and 36 to 48 hr.&#xD;
&#xD;
      Clinical laboratory tests and safety monitoring were conducted during both treatment periods&#xD;
      for each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">June 29, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hrs</time_frame>
    <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Cmax was obtained directly from experimental observations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of Maximum Observed Plasma Concentration)</measure>
    <time_frame>Up to 48 hrs</time_frame>
    <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Tmax was obtained directly from experimental observations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent Terminal Elimination Half-life)</measure>
    <time_frame>Up to 48 hrs</time_frame>
    <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. T1/2 was calculated as the natural log of 2 divided by the terminal phase rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</measure>
    <time_frame>Up to 48 hrs</time_frame>
    <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. AUC0-inf was calculated using the linear trapezoidal rule, using actual elapsed time values. If the actual time of sample collection was not available, the nominal time was used for the purpose of parameter estimation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion (UGE)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Post-dose urine was collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h collections. After collection, the total volume of each batch and collection time was recorded. UGE, including UGE(t1-t2) and total 0-24 h and 0-48 h UGE were calculated. UGE(t1-t2) was derived from urine volume (Vt1-t2) multiplied by glucose concentration divided by 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexagliflozin with exenatide injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablets, 20 mg</description>
    <arm_group_label>Bexagliflozin alone</arm_group_label>
    <arm_group_label>Bexagliflozin with exenatide injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide Injection</intervention_name>
    <description>Byetta® (Exenatide), 10 ug, bid, subcutaneous injection</description>
    <arm_group_label>Bexagliflozin with exenatide injection</arm_group_label>
    <other_name>Byetta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects who were between the ages of 18 and 65 years, inclusive, in&#xD;
             good health based on medical history, physical examination, electrocardiogram and&#xD;
             routine laboratory tests.&#xD;
&#xD;
          2. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          3. Subjects who were non-smokers for at least 3 months prior to screening.&#xD;
&#xD;
          4. Subjects with adequate venous access at multiple sites in both arms.&#xD;
&#xD;
          5. Subjects who were willing and able to be confined to the clinical research facility as&#xD;
             required by the protocol.&#xD;
&#xD;
          6. Subjects who had the ability to comprehend and who were willing to provide written&#xD;
             informed consent in accordance with institutional and regulatory guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who were determined by the investigator or sub-investigator to be unsuitable&#xD;
             for participation in the study based on medical conditions or factors that would have&#xD;
             influenced adherence to study activities.&#xD;
&#xD;
          2. Subjects with a clinically significant history of allergy to drugs or latex.&#xD;
&#xD;
          3. Subjects with a history of hypoglycemia.&#xD;
&#xD;
          4. Subjects with a history of alcohol or drug dependence in the last 12 months.&#xD;
&#xD;
          5. Subjects who donated 400 mL of whole blood within 56 days, 200 mL of whole blood&#xD;
             within one month, or donated blood components within 14 days of screening.&#xD;
&#xD;
          6. Subjects who used prescription or over-the-counter (OTC) drugs within 14 days prior to&#xD;
             the first dose.&#xD;
&#xD;
          7. Subjects who used vitamin preparations or supplements (including St. John's Wort and&#xD;
             ginseng) within 14 days prior to the first dose .&#xD;
&#xD;
          8. Subjects who were not willing to refrain from smoking, alcohol, grapefruit, grapefruit&#xD;
             juice or related products, caffeine consumption (including chocolate), and strenuous&#xD;
             exercise within 72 h prior to Day 1 and through the end of the PK study.&#xD;
&#xD;
          9. Male subjects who did not agree to refrain from donating sperm and use appropriate&#xD;
             birth control methods including condoms with spermicide, female partner's use of&#xD;
             diaphragm with spermicide, or stable oral, implanted, or injected contraceptive&#xD;
             hormones, or with an intrauterine device, or female partner is surgically sterile&#xD;
             (i.e. have undergone partial or full hysterectomy, or bilateral oophorectomy) or&#xD;
             postmenopausal (absence of menses greater than 12 months and age &gt;45 years), for a&#xD;
             period of 30 days after discharge from the clinic.&#xD;
&#xD;
         10. Female subjects of childbearing potential who were not willing to use an adequate&#xD;
             method of contraception including bilateral tubal ligation, intrauterine device,&#xD;
             diaphragm with spermicide and male partner's use of male condom with spermicide, and&#xD;
             to not become pregnant for the duration of the study. Female subjects who were&#xD;
             surgically sterile (partial or full hysterectomy, or bilateral oophorectomy) or&#xD;
             postmenopausal (absence of menses greater than 12 months and age &gt;45 years) were&#xD;
             eligible if they tested negative on the pregnancy test.&#xD;
&#xD;
         11. Subjects who had been treated with an investigational drug within 30 days or 7&#xD;
             half-lives of the investigational drug, whichever is longer, prior to the first dose&#xD;
             of study drug in this trial.&#xD;
&#xD;
         12. Subjects who had previously received exenatide, or any other GLP-1 RAs within three&#xD;
             months from the screening or subjects who had had any GLP-1 RA and suffered an adverse&#xD;
             reaction due to the medication.&#xD;
&#xD;
         13. Subjects who had previously received bexagliflozin, or any other SGLT2 inhibitors&#xD;
             within 3 months from the screening.&#xD;
&#xD;
         14. Subjects whose screening ECG demonstrates any one of the following: heart rate &gt;100&#xD;
             bpm, QRS &gt;120 msec, QTc &gt;470 msec (corrected by Fridericia's formula), PR &gt;220 msec (a&#xD;
             subject with PR &gt;220 msec was generally to be excluded but exceptions may have been&#xD;
             allowed at the discretion of the investigator), or any clinically significant&#xD;
             arrhythmia.&#xD;
&#xD;
         15. Subjects whose sitting blood pressure was above 140/90 mmHg at screening. If the&#xD;
             sitting blood pressure at screening was above 140/90 mmHg, one repeat measurement was&#xD;
             allowed and the subject may have been randomized if the blood pressure was 140/90 +/-5&#xD;
             mm Hg at the discretion of the Investigator.&#xD;
&#xD;
         16. Subjects who had a positive result of hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             virus (HCV) antibody, urinary drug or urinary cotinine test.&#xD;
&#xD;
         17. Subjects with human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         18. Subjects who had had a febrile illness within 5 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
         19. Subjects vaccinated within 30 days (with the exception of the flu vaccine) prior to&#xD;
             the first dose of investigational drug.&#xD;
&#xD;
         20. Subjects with a history of acute or chronic pancreatitis or gall stones.&#xD;
&#xD;
         21. Positive urine glucose at screening.&#xD;
&#xD;
         22. Subjects with estimated glomerular filtration rate (eGFR) &lt;90 mL/min/1.73 m2 or a&#xD;
             history of kidney transplant.&#xD;
&#xD;
         23. Subjects with digestion problems, including gastroesophageal reflux disease, irritable&#xD;
             bowel syndrome, gastroparesis, and any other disorder deemed by the investigator to be&#xD;
             clinically significant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>March 25, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03167411/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03167411/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 healthy subjects were randomly assigned to one of the two groups (1 or 2) and will receive both treatments alternately, in a crossover fashion (two-period, two-treatment crossover design), with the two treatment groups separated by a 7-day washout period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bexagliflozin, Then Bexagliflozin With Exenatide</title>
          <description>After an overnight fast, subjects received a single oral dose of bexagliflozin tablets, 20 mg alone 30 min before breakfast. After a washout period of 7 days, the subjects then received a subcutaneous injection of exenatide 10 µg at 30 min prior to a single oral dose of bexagliflozin, and 1 hr before breakfast and followed by the second dose of exenatide alone 1 hr prior to the evening meal.</description>
        </group>
        <group group_id="P2">
          <title>Bexagliflozin With Exenatide, Then Bexagliflozin Alone</title>
          <description>Subjects received a subcutaneous injection of exenatide at 10 µg twice a day (bid) with an initial dose 30 min prior to a single oral dose of bexagliflozin tablets, 20 mg, and 1 hr before breakfast, followed by the second dose of exenatide alone 1 hr prior to the evening meal. After a washout period of 7 days, the subjects then received a single oral dose of bexagliflozin tablets, 20 mg alone 30 min before breakfast.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bexagliflozin, Then Bexagliflozin With Exenatide</title>
          <description>After an overnight fast, subjects received a single oral dose of bexagliflozin tablets, 20 mg alone 30 min before breakfast. After a washout period of 7 days, the subjects then received a subcutaneous injection of exenatide 10 µg at 30 min prior to a single oral dose of bexagliflozin, and 1 hr before breakfast and followed by the second dose of exenatide alone 1 hr prior to the evening meal.</description>
        </group>
        <group group_id="B2">
          <title>Bexagliflozin With Exenatide, Then Bexagliflozin</title>
          <description>Subjects received a subcutaneous injection of exenatide at 10 µg twice a day (bid) with an initial dose 30 min prior to a single oral dose of bexagliflozin tablets, 20 mg, and 1 hr before breakfast, followed by the second dose of exenatide alone 1 hr prior to the evening meal. After a washout period of 7 days, the subjects then received a single oral dose of bexagliflozin tablets, 20 mg alone 30 min before breakfast.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="9.03"/>
                    <measurement group_id="B2" value="43.1" spread="14.79"/>
                    <measurement group_id="B3" value="39.1" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="10.48"/>
                    <measurement group_id="B2" value="80.7" spread="17.29"/>
                    <measurement group_id="B3" value="79.1" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.1" spread="9.66"/>
                    <measurement group_id="B2" value="170.8" spread="10.94"/>
                    <measurement group_id="B3" value="172.0" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="3.45"/>
                    <measurement group_id="B2" value="27.3" spread="3.14"/>
                    <measurement group_id="B3" value="26.6" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.1" spread="11.98"/>
                    <measurement group_id="B2" value="106.3" spread="8.11"/>
                    <measurement group_id="B3" value="107.7" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Cmax was obtained directly from experimental observations.</description>
        <time_frame>Up to 48 hrs</time_frame>
        <population>Number of subjects in the PK population with data</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin With Exenatide</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Cmax was obtained directly from experimental observations.</description>
          <population>Number of subjects in the PK population with data</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="33.6"/>
                    <measurement group_id="O2" value="121.6" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of the least squares (LS) geometric means of Cmax when bexagliflozin is dosed in combination with exenatide versus when dosed alone, with 80-125% defined as the lack of interaction boundaries. 90% confidence intervals was constructed.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>125.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>104.45</ci_lower_limit>
            <ci_upper_limit>150.24</ci_upper_limit>
            <estimate_desc>Estimated ratio (%) of exponentiated mean difference of log-transformed PK parameter from ANOVA (linear mixed-effects model), with treatment, period, and sequence as fixed effects, and subject as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
        <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Tmax was obtained directly from experimental observations.</description>
        <time_frame>Up to 48 hrs</time_frame>
        <population>Number of subjects in the PK population with data</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin With Exenatide</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time of Maximum Observed Plasma Concentration)</title>
          <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. Tmax was obtained directly from experimental observations.</description>
          <population>Number of subjects in the PK population with data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="5.00" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
        <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. T1/2 was calculated as the natural log of 2 divided by the terminal phase rate constant.</description>
        <time_frame>Up to 48 hrs</time_frame>
        <population>Number of subjects in the PK population with data</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin With Exenatide</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (Apparent Terminal Elimination Half-life)</title>
          <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. T1/2 was calculated as the natural log of 2 divided by the terminal phase rate constant.</description>
          <population>Number of subjects in the PK population with data</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="45.3"/>
                    <measurement group_id="O2" value="8.8" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
        <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. AUC0-inf was calculated using the linear trapezoidal rule, using actual elapsed time values. If the actual time of sample collection was not available, the nominal time was used for the purpose of parameter estimation.</description>
        <time_frame>Up to 48 hrs</time_frame>
        <population>Number of subjects in the PK population with data</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin With Exenatide</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)</title>
          <description>Whole venous blood samples of 3 mL was collected from peripheral vein at each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose of bexagliflozin. A non-compartmental pharmacokinetic analysis was used to calculate the PK parameters. AUC0-inf was calculated using the linear trapezoidal rule, using actual elapsed time values. If the actual time of sample collection was not available, the nominal time was used for the purpose of parameter estimation.</description>
          <population>Number of subjects in the PK population with data</population>
          <units>hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776.0" spread="27.5"/>
                    <measurement group_id="O2" value="1085.3" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of the least squares (LS) geometric means of AUC0-inf when bexagliflozin is dosed in combination with exenatide versus when dosed alone, with 80-125% defined as the lack of interaction boundaries. 90% confidence intervals was constructed.</non_inferiority_desc>
            <param_type>Point Estimate (%)</param_type>
            <param_value>137.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>122.28</ci_lower_limit>
            <ci_upper_limit>154.75</ci_upper_limit>
            <estimate_desc>Estimated ratio (%) of exponentiated mean difference of log-transformed PK parameter from ANOVA (linear mixed-effects model), with treatment, period, and sequence as fixed effects, and subject as a random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose Excretion (UGE)</title>
        <description>Post-dose urine was collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h collections. After collection, the total volume of each batch and collection time was recorded. UGE, including UGE(t1-t2) and total 0-24 h and 0-48 h UGE were calculated. UGE(t1-t2) was derived from urine volume (Vt1-t2) multiplied by glucose concentration divided by 100.</description>
        <time_frame>0-48 hours</time_frame>
        <population>Number of subjects in the PD population with data in the specific category</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
          </group>
          <group group_id="O2">
            <title>Bexagliflozin With Exenatide</title>
            <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion (UGE)</title>
          <description>Post-dose urine was collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h collections. After collection, the total volume of each batch and collection time was recorded. UGE, including UGE(t1-t2) and total 0-24 h and 0-48 h UGE were calculated. UGE(t1-t2) was derived from urine volume (Vt1-t2) multiplied by glucose concentration divided by 100.</description>
          <population>Number of subjects in the PD population with data in the specific category</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (-12 to 0 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.140"/>
                    <measurement group_id="O2" value="0.05" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.32" spread="8.705"/>
                    <measurement group_id="O2" value="26.38" spread="8.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.89" spread="7.833"/>
                    <measurement group_id="O2" value="28.95" spread="6.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 - 36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.93" spread="6.934"/>
                    <measurement group_id="O2" value="22.16" spread="6.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 - 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="6.283"/>
                    <measurement group_id="O2" value="9.21" spread="6.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.21" spread="15.035"/>
                    <measurement group_id="O2" value="55.65" spread="12.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 - 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.70" spread="25.080"/>
                    <measurement group_id="O2" value="88.11" spread="20.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from Day 0 to Day 10.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bexagliflozin</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose</description>
        </group>
        <group group_id="E2">
          <title>Bexagliflozin With Exenatide</title>
          <description>Bexagliflozin: Bexagliflozin tablets, 20 mg, oral, one dose&#xD;
Exenatide: Byetta® (Exenatide), 10 µg, subcutaneous injection, twice a day (bid), two doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 630-2129</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

